FDA approves first at‐home brain therapy for resistant MDD
Abstract
The Food and Drug Administration (FDA) on Jan. 12 announced its approval of the first prescription, physician‐directed, at‐home brain neuromodulation therapy as an adjunctive treatment for adults with major depressive disorder (MDD) who failed to achieve satisfactory improvement from at least one previous antidepressant.
Fields of Study & Subjects
Transcranial Magnetic Stimulation Studies
Treatment of Major Depression
Electroconvulsive Therapy Studies
Publication details
- Journal / source
- Mental Health Weekly
- Volume
- 36
- Issue
- 3
- Pages
- 4–5
- Publication date
- 16 January 2026
- Language
- EN